Hanglok has successfully concluded its A round of financing, securing over 200 million yuan. Led by Daohe Healthcare, the financing round saw participation from Proxima Ventures, Yuansheng BioVenture, Huatai Zijin, Lvyong Ruihua, Kangze (Macau), and longstanding shareholder GREE Capital.

The funds raised will be allocated towards various initiatives including clinical trials, registration and application processes for puncture surgical robot products, team expansion, market outreach efforts, and ongoing research and development of pipeline products. This investment will further expedite the development and commercialization of Hanglok's surgical robot products.